Altogether these results suggest that UHRF1 may serve as a useful biomarker and therapeutic target for prostate cancer as it plays an important role in epigenetic silencing of TSGs via histone and DNA modifications. This evidence concerns the gene UHRF1 and Familial prostate cancer.